iShares MSCI Israel ETFEIS

The iShares MSCI Israel ETF (EIS) is a plain-vanilla tracker dressed in a Silicon Wadi marketing suit. The fund’s mandate is to provide exposure to Israeli equities via the MSCI Israel Index, with a 0.47% annual fee and a top-concentration cap of 5% per holding. On 26 July 2026, the fund’s holdings are whatever MSCI decided to include that quarter, not the AI and cyber dream team the issuer’s product pages imply. The fund’s official pages explicitly state that most UK regulatory protections do not apply and compensation will not be available under the UK Financial Services Compensation Scheme in the event of default.

EIS trades on Nasdaq under ticker EIS and is listed among iShares’ global range of ETFs. The issuer’s UK site uses images of highways, machinery and AI-centric visuals to suggest forward motion, but the fund itself is a static index with a quarterly rebalance cycle. The product pages for “AI ETFs” and “ETF investments” tout innovation and growth, yet the fund’s holdings are regulated by MSCI’s rules, not by any proprietary AI-selection screen. The fee is the only thing that grows reliably year after year.

The fund’s expense ratio is 0.47% per annum, according to the issuer’s UK product pages, which also note that UK protections largely do not apply to the fund’s operations. The fund’s holdings are capped at 5% per security and 50% in any single country, reflecting MSCI Israel Index rules. No specific earnings, revenue, cash, or asset-movement figures for EIS are provided on the issuer’s public pages; the fund’s structure is governed by MSCI’s methodology, not by periodic earnings disclosures.

To see the fund’s current market price, bid/ask spread, and intraday liquidity, consult Nasdaq’s EIS ticker page. The fund’s tracking method is full replication of the MSCI Israel Index, with quarterly index reviews; deviations from the index are due to fees, expenses, and trading costs, not active bets. The issuer’s pages emphasise that the fund is domiciled and listed in ways that may limit UK investor protections.

The fund’s holdings are not itemised on the public product page, but by mandate, EIS must hold the constituents of the MSCI Israel Index subject to the 5% cap and 50% country limits. The fund’s expense ratio of 0.47% is the primary drag on performance versus the index. There is no evidence in the issuer’s rails of special AI, cyber, or medtech screens, nor any indication that the fund deviates from MSCI’s rules. For a deeper look at the fund’s holdings and current costs, use the FINRA Fund Analyzer, which draws on SEC filings and issuer disclosures.

What changed recently? The fund’s holdings are updated quarterly by MSCI as part of the Israel Index review cycle; the issuer’s UK pages do not announce discretionary changes to the basket. The issuer’s rails do not supply specific holdings, weights, or recent rebalancing dates. For the fund’s current market mechanics and liquidity, check Nasdaq’s EIS page. For regulatory and fee details, read the issuer’s UK product pages. The gap between the thematic marketing and the plain index remains the most consistent feature of this wrapper.

The fund’s tracking error and expense ratio are the only moving parts investors can count on with certainty. The issuer’s AI-themed product pages and machinery imagery are marketing, not methodology. The fund’s actual mandate is to track MSCI Israel, capped and constrained, with a fee that accrues whether the index rises or falls.